ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire•12/11/2026•16:05 ET
0
Key Highlights
- ➤$602.5 million IPO and AbbVie private placement proceeds completed
- ➤$901.0 million cash, equivalents and investments expected to fund operations into 2030
- ➤Agazisiran advanced across three Phase 2 complement-disease trials
- ➤Onvuzosiran received FDA Fast Track designation for HAE prophylaxis
- ➤Third-quarter net loss widened to $28.1 million from $17.9 million
Expert Statements
Zhen Li, Ph.D., President and Chief Executive Officer of ADARx
“We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement. These financings provide the resources to advance three clinical-stage programs in parallel, bring two advanced preclinical candidates into the clinic, and support additional IND filings as we expand our pipeline”
Zhen Li, Ph.D., President and Chief Executive Officer of ADARx
“As the siRNA field evolves, we see tremendous opportunity to expand the range of diseases these therapeutics can address. We believe that our progress with differentiated liver-targeted programs and targeted delivery to extrahepatic tissues positions us to advance our mission of delivering life-changing treatments to patients with unmet medical needs.”
– Completed initial public offering (IPO) and concurrent private placement generating aggregate gross proceeds of approximately $602.5 million; cash position expected to fund operations into 2030 –
– Advanced three Phase 2 clinical trials for agazisiran for the treatment of complement-mediated diseases –
Get started
Create a free account to read the full story.